Atlas Labs: Gearing for Growth

Abstract

The case is structured around the infancy problems being faced by the firm Atlas Labs. As a start-up initiated by technocrats with limited financial resources, the firm is struggling to find the financial resources necessary to create adequate facilities to meet quality standards demanded by a sophisticated customer segment. The professional background and expertise of the promoters are impeccable; their goodwill with domestic customers is also very good. They have managed the firm with meager resources, high dedication and great personal sacrifices. The firm has no debt but its volume of operations is constrained by facilities. If the firm fails to find a way out of this situation quickly, it would drift and would become unviable; or it would be grabbed by outsiders with the promoters not getting due return. The firm’s constitution is not ideally suited for the growth that is possible in the business sector. The challenge before the firm is about re-constitution, about finding the optimal financial structure to cater to long-term growth and about coming out of the current crisis. The firm needs to develop an action plan that builds in all these elements.

Keywords

Start-up bottlenecks of growth prioritization financial structure PE investment

Get full access to this article

View all access options for this article.

References

Abbot

Alison

. 2005. ‘Animal Testing: More than a Cosmetic Change’, Nature, 438: 144–46. Available at http://www.nature.com/nature/journal/v438/n7065/full/438144a.html (accessed on December 5, 2014).

Agency for Toxic Substances and Disease Registry. 1999. Case Studies in Environmental Medicines (CSEM), US Department of Health and Human Services, Public Health Service, National Institutes of health. Available at http://www.atsdr.cdc.gov/csem/lead/docs/lead.pdf (accessed on December 5, 2014).

Center for Drug Evaluation and Research. 1996. Guideline for Industry: Single Dose Acute Toxicity Testing for Pharmaceuticals, Federal Register, USFDA, August 1996. Available at http://www.fda.gov/downloads/Drugs/…/Guidances/ucm079270.pdf (accessed on December 5, 2014).

Global Industry Analysts Inc. 2011. ADME-Toxicology Testing: A Global Strategy Business Report. Available at http://www.strategyr.com/ADME_Toxicology_Testing_Market_Report.asp

Lalla

Jogender K.

Shah

Meena U.

Group

Edward F-III

. 2010. ‘Principal Animal Toxicity Studies’, International Journal of Pharma and Bio Sciences, V1(2). Available at http://www.ijpbs.net/issue-2/48.pdf (accessed on December 5, 2014).

National Research Council. 2007. Toxicity Testing in the 21st Century: A Vision and Strategy; National Academies Press, 500 Fifth Street, NW, Washington DC, 20001. Available at http://dels.nas.edu/resources/static-assets/materials-based-on-reports/reports-in-brief/Toxicity_Testing_final.pdf (accessed on December 5, 2014).

National Toxicology Program. 2000. NTP Technical Report on Toxicity Studies of Carisoprodol, CAS No. 78-44-4, Toxicity Report No. 56, US Department of Health and Human Sciences, Public Health Service, National Institutes of Health. Available at http://ntp.niehs.nih.gov/ntp/htdocs/ST_rpts/tox056.pdf (accessed on December 5, 2014).

Nuffield Council on Bioethics. 2000. The Ethics of Research Involving Animals: Animal use in Toxicity Studies (pp. 155–67), London: Nuffield Council on Bioethics. Available at http://www.nuffieldbioethics.org/sites/default/files/files/Animals%20Chapter%209%20Animal%20Use%20in%20Toxicity%20Studies.pdf (accessed on December 5, 2014).

Sengupta

Alokparna

. 2012. Toxicity Testing in India: An Animal Welfare Perspective, Federation of Indian Animal Protection Organisation and Humane Society International, April 2012. Available at http://www.fiapo.org/downloads/Alokparna_FIAPO_2012_Toxicity_testing_in_India.pdf (accessed on December 5, 2014).

10.

Van der Lan, Dr Jan William 2000. General Toxicity Study Designs—Selection of Safety of Medicines and Teratology, Centre for Biological Medicines and Medical Technology, National Institute for Public Health and Environment. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2009/10/WC500004193.pdf (accessed on December 5, 2014).

11.

1. www.advinus.com website of Advinus Therapeutics Ltd, Bangalore, India. (accessed on December 5, 2014).

12.

2. www.huntingdon.com/ website of Huntingdon Life Sciences USA. (accessed on December 5, 2014).

13.

3. www.inveresk-research website of Inveresk Research International USA. (accessed on December 5, 2014).

14.

4. www.jrfonline.com website of Jai Research Foundation, Vapi, Gujarat, India. (accessed on December 5, 2014).